Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 1997

View Archived Issues

Selective thrombin inhibitors revealed by HMR

MMP/TNF/CD23 inhibitors prepared by Chiroscience

Fujisawa describes new cephems

PNP inhibitors from Chiroscience for T-cell-mediated disorders

Orion-Yhtyma discloses potent and selective alpha2-adrenoceptor agonists

Excitatory amino acid antagonists disclosed by Glaxo Wellcome

Leukotriene biosynthesis inhibitors from Abbott

Gensia receives ANDA approval for etoposide injection

VIMRx acquires worldwide rights to wound-healing agent

SmithKline Beecham's Famvir receives U.K. approval for new indication

Chiroscience starts clinical development of PDE IV inhibitor

Biomet and Merck KGaA to form joint venture

DepoMed seeks alliances for drug delivery systems

Serzone superior to Prozac in the treatment of sleep disturbances in depressed patients

Company Profile: MitoKor

Somatix reports promising results from melanoma vaccine trials

Rhone-Poulenc Rorer launches Zagam in the U.S.

NIH funds Cognetix's research on antiseizure drug

Techniclone reports promising results from brain cancer treatment study

Preliminary phase I/II results for Vertex's VX-710

Preliminary results indicate potential for AML treatment

Ibex Technologies presents data on heparin neutralization agent

Merck updates development of higher dose Zocor

Pranlukast evaluated in numerous preclinical and clinical studies

Aronex reports clinical progress of Annamycin

Design of bisoprolol CIBIS II study

Additional GUSTO III data supports efficacy and safety of Retavase

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...